Teva's High Hopes for Custirsen
Teva is losing patent protection on its multi billion cancer drug Copaxone in 2015 and that has the company increasingly reliant on its pipeline. The company expects Phase 3 data early next year for Custirsen, a prostate drug it hopes will offset some of Copaxone's expected sales drop.
Why You Should Watch Sanofi, Salix, Akorn, and Isis Today
Sanofi, Salix, Akorn, and Isis are four stocks you should be watching today. Here’s why.